Premature ovarian failure: Etiology and possible prevention

Expert Review of Endocrinology and Metabolism

Volumn 4, Issue 2, 2009, Pages 173-181

  Blumenfeld, Zeev ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Fragile X; Genetic determinant; Gonadotoxicity; Gonadotrophin releasing hormone agonist; Hypergonadotropic amenorrhea; Premature ovarian failure

Indexed keywords

ANTINEOPLASTIC AGENT; CELL NUCLEUS RECEPTOR; CELL NUCLEUS RECEPTOR NR6A1; FOLLITROPIN RECEPTOR; FORKHEAD TRANSCRIPTION FACTOR; FORKHEAD TRANSCRIPTION FACTOR FOXL2; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 3; GONADORELIN ANTAGONIST; GROWTH DIFFERENTIATION FACTOR 9; OCTAMER TRANSCRIPTION FACTOR 4; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR DAZL; TRANSCRIPTION FACTOR FIGLA; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR GATA 6; TRANSCRIPTION FACTOR GATA LIKE PROTEIN 1; TRANSCRIPTION FACTOR LHX8; TRANSCRIPTION FACTOR NOBOX; TRANSCRIPTION FACTOR SOHLH1; TRANSCRIPTION FACTOR TAF4B; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHROMOSOME DELETION X; GALACTOSEMIA; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; HUMAN; IATROGENIC DISEASE; MUMPS; NONHUMAN; ORCHITIS; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; REVIEW; TURNER SYNDROME;

EID: 70049108330     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/17446651.4.2.173     Document Type: Review

References (47)

1. Hoek A, Schoemaker J, Drexhage HA. Premature ovarian failure and ovarian autoimmunity. Endocr. Rev. 18, 107-134 (1997).
2. Skillern A, Rajkovic A. Recent developments in identifying genetic determinants of premature ovarian failure. Sex. Dev. 2(4-5), 228-243 (2008).
3. Simpson JL. Genetic and phenotypic heterogeneity in ovarian failure: overview of selected candidate genes. Ann. NY Acad. Sci. 1135, 146-154 (2008).
4. Goswami D, Conway GS. Premature ovarian failure. Hum. Reprod. Update 11(4), 391-410 (2005).
5. Krauss CM, Turksoy RN, Atkins L, McLaughin C, Brown L, Page DC. Familial premature ovarian failure due to an interstitial deletion of the long arm of the 3 chromosome. N. Engl. J. Med. 317, 125-131 (1987).
6. Chen YT, Mattison DR, Feigenbaum L, Fukui H, Schulman JD. Reduction in oocyte number following prenatal exposure to a diet high in galactose. Science 214, 1145-1147 (1981).
7. Forges T, Monnier-Barbarino P, Leheup B, Jouvet P. Pathophysiology of impaired ovarian function in galactosaemia. Hum. Reprod. Update 12(5), 573-584 (2006).
8. Blumenfeld Z, von Wolff M. GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy. Hum. Reprod. Update 14(6), 543-552 (2008).
9. Morrison JC, Givens JR, Wiser WL, Fish SA. Mumps oophoritis: a cause of premature menopause. Fertil. Steril. 26, 655-659 (1975).
10. Blumenfeld Z, Halachmi S, Peretz BA et al. Premature ovarian failure - the prognostic application of autoimmunity on conception after ovulation induction. Fertil. Steril. 59, 750-755 (1993).
11. van Kasteren YM, Hoek A, Schoemaker J. Ovulation induction in premature ovarian failure: a placebo-controlled randomized trial combining pituitary suppression with gonadotropin stimulation. Fertil. Steril. 64, 273-278 (1995).
12. Bath LE, Wallace WH, Critchley HO. Late effects of the treatment of childhood cancer on die female reproductive system and the potential for fertility preservation. Br. J. Obstet. Gynaecol. 109, 107-114 (2002).
13. Sklar CA, Mertens AC, Mitby P et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J. Natl Cancer Inst. 98, 890-896 (2006).
14. Blumenfeld Z. GnRH-agonists in fertility preservation. Curr. Opin. Endocrinol. Diabetes Obes. 15, 523-528 (2008).
15. Matzuk MM, Lamb DJ. Genetic dissection of mammalian fertility pathways. Nat. Cell Biol. 4(Suppl.), S41-S49 (2002).
16. Simpson JL, Rajkovic A. Ovarian differentiation and gonadal failure. Semin. Med. Genet. 89, 186-200 (1999).
17. Meduri G, Touraine P, Beau I et al. Delayed puberty and primary amenorrhea associated with a novel mutation of the human follicle-stimulating hormone receptor: clinical, histological, and molecular studies. J. Clin. Endocrinol. Metab. 88, 3491-3498 (2003).
18. Ottolenghi C, Pelosi E, Tran J et al. Loss of Wnt4 and Foxl2 leads to female-to-male sex reversal extending to germ cells. Hum. Mol. Genet. 16, 2795-2804 (2007).
19. Reddy P, Liu L, Adhikari D et al. Oocyte-specific deletion of PTEN causes premature activation of the primordial follicle pool. Science 319, 611-613 (2008).
20. Ledig S, Ropke A, Haeusler G, Hinney B, Wieacker P. BMP15 mutations in XX gonadal dysgenesis and premature ovarian failure. Am. J. Obstet. Gynecol. 198, 84.e1-84.e5 (2008).
21. Zhao H, Chen Z, Qin Y et al. Transcription factor FIGLA is mutated in patients with premature ovarian failure. Am. J. Hum. Genet. 82, 1342-1348 (2008).
22. Anderson RA, Fulton N, Cowan G, Coutts S, Saunders PT. Conserved and divergent patterns of expression of DAZL, VASA and OCT4 in the germ cells of the human fetal ovary and testis. BMC Dev. Biol. 18, 136 (2007).
23. Kerr CL, Hill CM, Blumenthal PD, Gearhart JD. Expression of pluripotentic stem cell markers in the human fetal ovary. Hum. Reprod. 23, 589-599 (2008).
24. Pires ES, Meherji PK, Vaidya RR, Parikh FR, Ghosalkar MN, Khole W. Specific and sensitive immunoassays detect multiple anti-ovarian antibodies in women with infertility. J. Histochem. Cytochem. 55, 1181-1190 (2007).
25. Badawy A, Goda H, Ragab A. Induction of ovulation in idiopathic premature ovarian failure: a randomized double-blind trial. Reprod. Biomed. Online 15, 215-219 (2007).
26. Chang SH, Kim CS, Lee KS et al. Premenopausal factors influencing premature ovarian failure and early menopause. Maturitas 58(1), 19-30 (2007).
27. Matikainen T, Perez GI, Jurisicova A et al. Aromatic hydrocarbon receptor-driven Bax gene expression is required for premature ovaiian failure caused by biohazardous environmental chemicals. Nat. Genet. 28(4), 355-360 (2001).
28. Hoyer PB, Devine PJ, Hu X, Thompson KE, Sipes IG. Ovarian toxicity of 4-vinylcyclohexene diepoxide: a mechanistic model. Toxicol. Pathol. 29(1), 91-99 (2001).
29. Crain DA, Janssen SJ, Edwards TM et al. Female reproductive disorders: the roles of endocrine-disrupting compounds and developmental timing. Fertil. Steril. 90(4), 911-940 (2008).
30. American Cancer Society. Cancer Facts and Figures 2005. American Cancer Society, Atlanta, GA, USA (2005).
31. Nieman CL, Kazer R, Brannigan RE et al. Cancer survivors and infertility: a review of a new problem and novel answers. J. Support. Oncol. 4, 171-178 (2006).
32. Marhhom E, Cohen I. Fertility preservation options for women with malignancies. Obstet. Gynecol. Surv. 62, 58-72 (2007).
33. Beck-Fruchter R, Weiss A, Shalev E. GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data. Hum. Reprod. Update 14(6), 553-561 (2008).
34. Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil. Steril. 337(3), 195-206 (2008).
35. Ataya K, Rao LV, Laurence E, Kimmel R. Luteinizing hormone-releasing agonist inhibits cyclophosphamide induced ovarian follicular depletion in Rhesus monkeys. Biol. Reprod. 52, 365-372 (1995).
36. Imai A, Sugiyama M, Furui T, Tamaya T, Ohno T. Direct protection by a gonadotropin-releasing hormone analog from doxorubicin-induced granulosa cell, damage. Gynecol. Obstet. Invest. 63, 102-106 (2007).
37. Edgar AB, Wallace WHB. Pregnancy in women who had cancer in childhood. Eur. J. Cancer 43, 1890-1894 (2007).
38. Sklar CA, Mertens AC, Mitby P et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J. Natl Cancer Inst. 98, 890-896 (2006).
39. Blumenfeld Z, Avivi I, Eckman A et al. Gonadotropin releasing hormone agonist decreases chemotherapy induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma. Fertil. Steril. 89, 166-173 (2008).
40. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist 12, 1044-1054 (2007).
41. Moore HCF. Ovarian failure after chemotherapy for breast cancer and the role of gonadotropin-releasing hormone analogs in protection of ovarian function. In: ASCO 2008 Educational Book - 44th Annual Meeting May 30-June 3 2008, Chicago, IL. Govindan R, Curzio J (Eds). American Society of Clinical Oncology, Alexandria, VA, USA 39-42 (2008).
42. Recchia F, Saggio G, Amiconi G et al. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 106, 514-523 (2006).
43. Del Mastro L, Catzeddu T, Boni L et al. Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young early breast cancer patients. Ann. Oncol. 17, 74-78 (2006).
44. Cuzick J, Ambroisine L, Davidson N et al. LHRH-Agonists in Early Breast Cancer Overview group. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 369, 1711-1723 (2007).
45. Sharma R, Hamilton A, Bekh J. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst. Rev. 4, CD004562 (2008).
46. Knight PG, Glister C. TGF-β superfamily members and ovarian follicle development. Reproduction 132, 191-206 (2006).
47. Blumenfeld Z, Benaroush M, Zuckerman T. Spontaneous pregnancy and normal delivery after repeated autologous bone marrow transplantation and GnRH agonist treatment. Hum. Reprod. 22, 2346 (2007).